Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcus Biosciences Inc (NY: RCUS )

20.68 -0.66 (-3.09%)
Official Closing Price Updated: 6:30 PM EST, Feb 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 453,043
Open 21.24
Bid (Size) 20.37 (1)
Ask (Size) 23.24 (1)
Prev. Close 21.34
Today's Range 20.67 - 21.75
52wk Range 16.74 - 39.75
Shares Outstanding 72,407,706
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Arcus Biosciences to Participate at Upcoming Virtual Investor Events
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire

Performance

YTD
+2.38%
+2.38%
1 Month
+18.10%
+18.10%
3 Month
-16.24%
-16.24%
6 Month
-18.03%
-18.03%
1 Year
-31.73%
-31.73%

More News

Read More
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Where Arcus Biosciences Stands With Analysts
Via Benzinga
Expert Ratings for Arcus Biosciences
Via Benzinga
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
Via Investor's Business Daily
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Stock Market Falls Sharply Again As Tesla Dives, Micron Hits Chips; Nike, FedEx Strong: Weekly Review
Via Investor's Business Daily
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data
Via InvestorPlace
Dow Jumps 150 Points; Crude Oil Rises 1%
Via Benzinga
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Edges Lower; Gold Rises 1.5%
Via Benzinga
Arcus Biosciences, FuelCell Energy And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche
Via Investor's Business Daily
US Stocks Edge Higher; Dow Rises 50 Points
Via Benzinga
Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients
Via Benzinga
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
Via FinancialNewsMedia
Exposures Product Safety
Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges
Via Investor's Business Daily
Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures
Via Benzinga
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.